SIGHT SCIENCES INC (SGHT) Stock Price, Quote, News and Overview
NASDAQ:SGHT - Nasdaq - US82657M1053 - Common Stock - Currency: USD
SGHT Quote, Performance and Key Statistics
3.05
-0.03 (-0.97%)
The current stock price of SGHT is 3.05 USD. In the past month the price increased by 36.77%. In the past year, price decreased by -48.83%.
SGHT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.79 | 230.35B | ||
| ISRG | INTUITIVE SURGICAL INC | 69.3 | 189.75B | ||
| BSX | BOSTON SCIENTIFIC CORP | 38.86 | 155.20B | ||
| SYK | STRYKER CORP | 30.19 | 144.36B | ||
| MDT | MEDTRONIC PLC | 15.89 | 108.82B | ||
| BDX | BECTON DICKINSON AND CO | 11.98 | 48.46B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.1 | 44.47B | ||
| IDXX | IDEXX LABORATORIES INC | 41.39 | 38.24B | ||
| RMD | RESMED INC | 26.43 | 35.18B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.33 | 32.29B | ||
| DXCM | DEXCOM INC | 49.47 | 32.00B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.3 | 24.05B |
Related stock screener links
About SGHT
Company Profile
Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company is headquartered in Menlo Park, California and currently employs 216 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Company Info
SIGHT SCIENCES INC
4040 Campbell Ave,, Suite 100
Menlo Park CALIFORNIA US
CEO: Paul Badawi
Employees: 214
Phone: 14158890550
SIGHT SCIENCES INC / SGHT FAQ
What is the stock price of SIGHT SCIENCES INC today?
The current stock price of SGHT is 3.05 USD. The price decreased by -0.97% in the last trading session.
What is the ticker symbol for SIGHT SCIENCES INC stock?
The exchange symbol of SIGHT SCIENCES INC is SGHT and it is listed on the Nasdaq exchange.
On which exchange is SGHT stock listed?
SGHT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SIGHT SCIENCES INC stock?
14 analysts have analysed SGHT and the average price target is 3.49 USD. This implies a price increase of 14.26% is expected in the next year compared to the current price of 3.05. Check the SIGHT SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SIGHT SCIENCES INC worth?
SIGHT SCIENCES INC (SGHT) has a market capitalization of 157.69M USD. This makes SGHT a Micro Cap stock.
How many employees does SIGHT SCIENCES INC have?
SIGHT SCIENCES INC (SGHT) currently has 214 employees.
What are the support and resistance levels for SIGHT SCIENCES INC (SGHT) stock?
SIGHT SCIENCES INC (SGHT) has a support level at 3.04 and a resistance level at 3.15. Check the full technical report for a detailed analysis of SGHT support and resistance levels.
Is SIGHT SCIENCES INC (SGHT) expected to grow?
The Revenue of SIGHT SCIENCES INC (SGHT) is expected to decline by -10.21% in the next year. Check the estimates tab for more information on the SGHT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SIGHT SCIENCES INC (SGHT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SGHT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SGHT, evaluating the profitability, health, valuation and growth aspects
- SIGHT SCIENCES INC (SGHT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SIGHT SCIENCES INC (SGHT) Sales and EPS estimates to see what analysts future expectations are.
- SIGHT SCIENCES INC (SGHT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SIGHT SCIENCES INC (SGHT) Insider and Institutional Ownership to learn about the owners and their transactions.
- SIGHT SCIENCES INC (SGHT) Stock Chart to make your own analysis
- SIGHT SCIENCES INC (SGHT) Latest news and press-releases to stay up to date.
Does SIGHT SCIENCES INC (SGHT) stock pay dividends?
SGHT does not pay a dividend.
When does SIGHT SCIENCES INC (SGHT) report earnings?
SIGHT SCIENCES INC (SGHT) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of SIGHT SCIENCES INC (SGHT)?
SIGHT SCIENCES INC (SGHT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.03).
What is the Short Interest ratio of SIGHT SCIENCES INC (SGHT) stock?
The outstanding short interest for SIGHT SCIENCES INC (SGHT) is 3.66% of its float. Check the ownership tab for more information on the SGHT short interest.
SGHT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SGHT. When comparing the yearly performance of all stocks, SGHT is a bad performer in the overall market: 78.08% of all stocks are doing better.
SGHT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SGHT. The financial health of SGHT is average, but there are quite some concerns on its profitability.
SGHT Financial Highlights
Over the last trailing twelve months SGHT reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 9.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.06% | ||
| ROE | -58.85% | ||
| Debt/Equity | 0.45 |
SGHT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 74% to SGHT. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -8.52% and a revenue growth -10.21% for SGHT